1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations

Daniel P. Petrylak(Yale University), Xīn Gào(Qingdao University), Richard Gedrich(Arvinas (United States)), Arash Rezazadeh Kalebasty(University of California, Irvine), Diane Healey(Arvinas (United States)), J. Parameswaran(Arvinas (United States)), Ivor Percent(Florida Cancer Specialists & Research Institute), Maha Hussain(Northwestern University), Benjamin Garmezy(Sarah Cannon), Thomas Yu(Sage Bionetworks), Oliver Sartor(Mayo Clinic), Neeraj Agarwal(University of Utah), John Shen(University of California, Los Angeles), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Robert Dreicer(University of Virginia), Cora N. Sternberg(Cornell University)
Annals of Oncology
October 1, 2023
10.1016/j.annonc.2023.09.2751
Cited by 10

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k